April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
‘Three Strikes’ Anti-VEGF Retreatment Regime for Lucentis and Avastin in Age-Related Subretinal Neovascularisation: 3 Year Follow-Up - Effectiveness and Retreatment Injection Numbers Are Comparable to Treat and Extend Regimens
Author Affiliations & Notes
  • J. A. Patterson
    Hillingdon hospital & Western Eye Hosp - Visual Neuroscience, Imperial College, London, United Kingdom
  • N. Lee
    Hillingdon Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships  J.A. Patterson, None; N. Lee, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2059. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. A. Patterson, N. Lee; ‘Three Strikes’ Anti-VEGF Retreatment Regime for Lucentis and Avastin in Age-Related Subretinal Neovascularisation: 3 Year Follow-Up - Effectiveness and Retreatment Injection Numbers Are Comparable to Treat and Extend Regimens. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2059.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : In current clinical practice there are several retreatment regimen paradigms in use for age-related subretinal neovascularisation (SRNVM). Detailed prospective trials (CATT, IVAN) are currently underway to answer questions about which regimen is most suitable. The optimal retreatment regime for age-related SRNVM is currently a matter for debate.Experience of the anti-VEGF regime used at Hillingdon Hospital, London, is detailed. After diangnosis and an initial 3 loading anti-VEGF injections, any reaccumulation of intraretinal fluid received 3 intravitreal anti-VEGF injections spaced one month apart. This regimen is compared with other retreatment approaches (e.g. monthly treatment, treat & extend).

Methods: : 403 patients who received intravitreal Lucentis (n=261) or Avastin (n=142) and completed 3 year followup at Hillingdon Hospital for age-related SRNVM from introduction of anti-VEGF treatment were included in this review. Visual outcomes using Logmar Visual acuity were measured and outcomes charted. Local and systemic adverse events were monitored.

Results: : Baseline characteristics for patients receiving Lucentis & Avastin were not significantly different. A policy of three retreatment injections produced visual improvement gains comparable to the ANCHOR & MARINA trials in the first year of treatment, with both Lucentis (+13 letters) and Avastin (+11 letters). These gains were maintained over a three year follow-up period, with a mean number of injections of 6 in the first year (5.8/y Lucentis, 5.7/y Avastin), 6/y in the second year, and 5/y in year 3 of treatment. There were no local injection-related ocular complications in either group.

Conclusions: : A policy of three retreatment injections is a cost-effective and practical method of improving and maintaining central visual acuity in age-related SRNVM. This retreatment regimen produces equivalent efficacy in comparison to the trial gold standard of monthly injections, with fewer injections than in a monthly, or treat and extend, regimens. Efficacy was shown for both Lucentis and Avastin over the 3 year period under review. This regimen is recommended to maximise therapeutic impact of anti-VEGF therapy in age-related SRNVM, given the large numbers of patients presenting who need this sight-saving treatment.

Keywords: age-related macular degeneration • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×